As COVID-19 Vaccine Sales Surge, BioNTech Pledges 40% Will Go To Poorer Nations
EU Adds Huge 1.8 Billion Dose Order
Angela Merkel consulted company’s CEO before opposing IP waiver, backing the future of Germany’s new ‘big biotech’ company.
You may also be interested in...
Coronavirus Notebook: South Africa To Build mRNA Vaccine Tech Transfer Hub, EMA OKs More Comirnaty Production Capacity
MSF is pressuring Moderna and Pfizer/BioNTech to share their vaccine know-how with manufacturers in developing countries, and companies have just a few days to answer the European Commission's questions about COVID-19 therapies they have in development.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
IP experts share views on a range of critical issues around the proposed US-backed patent waiver for COVID-19 vaccines. Proprietary materials once public can’t be pulled back, one cautioned, while others indicated the waiver risk may be the stick that pushes companies to toe the tech transfer line.